Page Image

HR Breast Cancer

ASCO 2025 Highlights: Dr. Rebecca Shatsky on Evolving Therapies in HR+ Breast Cancer
New drugs like vepdegestrant and oral SERDs may reshape HR+ breast cancer treatment with novel mechanisms and CDK4/6 combos.
Advertisement
Advertisement
;

Expert Interviews